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Abstract  
Oropharyngeal squamous cell carcinoma (OPSCC) incidence has increased dramatically 
due to human papillomavirus (HPV); however, associated epigenetic alterations are not 
well studied. We performed genome-wide DNA methylation analysis using an Infinium 
450k BeadArray for clinical OPSCC and non-cancerous samples and cancer cell lines 
with/without 5-aza-2ʹ-deoxycytidine and/or trichostatin A treatment. Frequent promoter 
hypermethylation and methylation-associated silencing were detected in 144 genes, 
which included those involved in cell-cell signaling and neuron differentiation. The 
methylation of nine genes (GHSR, ITGA4, RXRG, UTF1, CDH8, FAN19A4, CTNNA2, 
NEFH, and CASR) was quantitatively validated in 70 pharyngeal SCC cases by 
pyrosequencing. Hypermethylation significantly correlated with HPV-L1 positivity, but 
not with age or smoking status. p16INK4A was generally activated in HPV-L1(+) tumors, 
and p16-positive cases significantly associated with better prognosis. RXRG 
hypermethylation strongly correlated with positivity of HPV-L1 and p16 (P=3×10-5 and 
P=5×10-4, respectively). RXRG-methylation(+) significantly associated with better 
prognosis when analyzing all tumor cases (P=0.04), and when analyzing the p16-
negative poorer-outcome group (P=0.03). Thus, aberrant DNA methylation might be 
involved in HPV-associated OPSCC; in addition, DNA methylation could serve as a 
marker to classify subgroups based on outcome.  
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1. Introduction  
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
cancer worldwide; its annual incidence is 600,000 cases, accounting for 3–5% of all 
cancers [1]. In particular, the incidence of oropharyngeal squamous cell carcinoma 
(OPSCC) has increased over the last two decades, mainly because the number of human 
papillomavirus (HPV)-associated OPSCC cases has risen dramatically [2, 3]. HPV-
associated and HPV-negative OPSCCs are clinically and biologically distinct. The 
major risk factors for HPV-negative tumors are tobacco and excessive alcohol use. In 
contrast, HPV-associated tumors are strongly associated with sexual behavior [4]. 
Compared to patients with HPV-negative tumors, those with HPV-associated tumors 
tend to be younger, have higher socioeconomic status, and have disease with lower 
primary stages and high nodal stages [5]. Regarding prognosis, it was shown that 
HPV(+) status is a consistent determinant
 
of better prognosis, regardless of treatment 
modality, with 5-year survival rates among patients with HPV-associated tumors of 
approximately 75–80% versus 45–50% among patients with HPV-negative tumors [6]. 
HNSCCs, especially HPV-negative tumors, are thought to initiate and progress 
through a series of genetic alterations caused by smoking and excessive alcohol intake. 
Several tumor suppressive genes are indeed dysregulated through genetic alterations, 
such as TP53 and CDKN2A, which are associated with the highest mutation rates, based 
on TCGA data for HNSCC [7]. The prevalence of TP53 and CDKN2A mutations in 
HNSCC ranges from 30 to 84% and 4 to 74%, respectively, according to various studies 
[8-10]. However, these two genes are not mutated in HPV-associated tumors; instead, 
TP53 is inactivated by the E6 oncoprotein [11-14]. HPV induces cancer by infecting 
epithelial basal cells. Initially after infection, HPV can be identified in circular extra 
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chromosomal particles or episomes. Then, the viral genome typically integrates into the 
host cell genome, resulting in upregulated expression of viral E6 and E7 oncoproteins 
[10, 15]. E6 and E7 proteins bind to and inactivate the tumor suppressors TP53 and RB1 
respectively. This enables the host cells to avoid apoptosis and leads to proliferation 
[13]. In addition, cell cycle pathway feedback results in overstimulation of cell 
senescence pathways including p16INK4A. We can therefore use p16INK4A expression as a 
surrogate marker for HPV infection [16]. HPV infection is generally evaluated by 
detection of the HPV viral oncogenes E6 and E7 using quantitative reverse 
transcriptase-PCR (RT-PCR) on RNA isolated from fresh frozen samples, or also by 
detection of L1 region of HPV by PCR combined with immunostaining of p16INK4A [16-
19]. 
DNA methylation is one of the key epigenetic mechanisms that regulates gene 
expression, and aberrant DNA hypermethylation of gene promoter regions is a major 
inactivating mechanism to silence tumor suppressor genes in most cancers [20]. In 
particular, virus infection could induce aberrant DNA methylation during carcinogenesis 
[21, 22]. Therefore, differences in methylation profiles between HPV-associated and 
HPV-negative OPSCCs have been explored in several studies. Whereas a limited 
number of similar genes have been investigated, e.g. TIMP3 and p16INK4A [23], detailed 
DNA methylation profiles of OPSCC have not been analyzed. Moreover, the molecular 
mechanisms responsible for clinical differences between patients with HPV-associated 
and HPV-negative tumors have not been clarified. 
In this study, we performed DNA methylation analysis of OPSCC on a genome-
wide scale. We identified candidate methylation-associated genes by Infinium 450k 
methylome analysis of clinical OPSCC and non-cancerous mucosa samples, and RNA-
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sequencing (RNA-seq) analysis combined with Infinium 450k analysis for cancer cell 
lines treated with/without 5-aza-2ʹ-deoxycytidine (Aza) and/or trichostatin A (TSA). We 
validated methylation status using additional clinical samples by pyrosequencing, and 
compared methylation status with clinicopathological factors, revealing a significant 
association with critical factors such as HPV status and prognosis.  
 
6/34		
2. Materials and methods  
2.1 Clinical samples and cell lines  
Clinical specimens were collected from 70 patients with pharyngeal squamous 
cell carcinoma (PSCC) who underwent therapy at Chiba University Hospital or 
Hamamatsu University hospital and written informed consent was obtained. Biopsy 
specimens were immediately frozen in liquid nitrogen and stored at -80 ºC. Frozen 
materials were microscopically examined by two independent pathologists and were 
dissected to enrich cancer cells when necessary. Fifty-three samples containing >50% 
cancer cells were used for subsequent molecular analyses. Seventeen samples were 
extracted from formalin-fixed paraffin-embedded (FFPE) tissues. The UMSCC47 cell 
line, derived from a primary tumor of the lateral tongue, was kindly provided by Dr. 
Thomas E. Carey, University of Michigan. The FaDu cell line, derived from primary 
hypopharyngeal SCC, was obtained from the ATCC. DNA was extracted by using a 
QIAquick DNA mini-kit (Qiagen, Hilden, Germany). The protocol was approved by the 
institutional review board at Chiba University and Hamamatsu University.  
 
2.2 Immunohistochemistry (IHC) 
IHC for TP53 was conducted using a DO-7 anti-mouse monoclonal antibody 
(anti-p53 DO-7 Primary Antibody, Roche, Basel, Switzerland) and the BenchMark 
ULTRA automated staining system (Roche). Samples with diffuse strong positive 
nuclear staining were considered TP53-IHC(+) and designated as TP53-mutation(+), 
those with negative nuclear staining were considered TP53-IHC(-) and designed as 
TP53-mutation(+), and those with sporadic positive nuclear staining were considered 
TP53-IHC wild-type and designed as TP53-mutation(-). For p16INK4A, IHC was 
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performed using an anti-mouse monoclonal antibody (CINtec p16 Histology, Roche) 
and BenchMark ULTRA, and samples with positive nuclear staining (nuclear and 
cytoplasmic immunoreactivity in >70% of tumor cells) were considered p16-IHC(+) 
and designated as p16(+). 
 
2.3 Amplification of L1 DNA region in high risk HPV  
Evaluation of HPV infection was also performed by amplifying a portion of the 
L1 region in high risk HPV using GP5 and GP6 primers, as previously reported [24]. 
Samples with the PCR amplicon was designated as HPV-L1(+).  
 
2.4 Aza and TSA treatment 
UMSCC47 and FaDu cells were seeded at a density of 3×105 cells/10-cm dish on 
day 0. Cells were exposed to Aza (3 µM for UMSCC47 and 5 µM for FaDu) or vehicle 
(DMSO) on days 1, 2, and 3. Cells were exposed to TSA (300 nM for UMSCC47 and 
100 nM for FaDu) or vehicle (ethanol) on day 3. Medium was changed every 24 h, and 
cells were harvested on day 4.  
 
2.5 Infinium assays  
The Infinium HumanMethylation450 BeadChip (Illumina) contains 
approximately 485,000 individual CpG sites covering 99% of RefSeq genes with an 
average of 17 CpG sites per gene. For each CpG site, β-value, ranging from 0.00 to 
1.00, was measured by a methylated probe relative to the sum of both methylated and 
unmethylated probes. Bisulfite conversion was performed using the Zymo EZ DNA 
Methylation Kit (Zymo Research, Irvine, CA) with 500 ng of genomic DNA for each 
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sample. Whole genome amplification, labeling, hybridization, and scanning were 
performed according to the manufacturer’s protocols. Infinium analysis was performed 
against 13 clinical OPSCC, four non-cancerous mucosa samples, and cancer cell lines 
treated with/without Aza and/or TSA (Fig. 1A), and Infinium data were submitted to the 
GEO database under the accession numbers GSM2612419 –GSM2612439. 
For analysis of DNA methylation at promoter regions based on Infinium data, the 
probe nearest to the transcription start site (TSS) was selected when multiple probes 
were designed for one promoter region. The CpG score for each probe was calculated 
based on a previous report [25, 26]. For analysis of CpG island shore regions upstream 
and downstream from TSS, the probe nearest to TSS was selected among probes at CpG 
island shore (annotated by Illumina). For analysis of gene body, the probe showing the 
highest CpG score was selected among probes at gene body, i.e. +4 kb downstream 
from TSS through the transcription terminal site.  
 
2.6 RNA-seq analysis  
Libraries for RNA-seq were prepared using the TruSeq Stranded mRNA Sample 
Prep Kit (Illumina, San Diego, CA), following the manufacturer’s protocol. Deep 
sequencing was performed on the Illumina HiSeq 1500 platform using the TruSeq 
Rapid SBS Kit (Illumina) in 50-base single-end mode according to the manufacturer’s 
protocol. RNA-seq analysis was performed against cancer cell lines treated with/without 
Aza and/or TSA (Fig. 1A), and RNA-seq data were submitted to the GEO database 
under the accession numbers GSM2612408 – GSM2612411.  
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2.7 Gene Ontology (GO) analysis  
Gene annotation enrichment analysis was conducted based on GO (biologic 
process, cellular component, and molecular function) using the Functional Annotation 
tool at DAVID Bioinformatics Resources (http://david.abcc.ncifcrf.gov/). 
 
2.8 Pyrosequencing analysis  
Quantitative validation of methylation in 70 cases was performed by 
pyrosequencing using the PyroMark Q96 (Qiagen) as previously reported [26]. Primers 
were designed by Pyro Q-CpG Software (Qiagen) to amplify bisulfite-treated DNA 
(Supplementary Table S1). Methylation control samples (0%, 25%, 50%, 75%, and 
100%) were prepared as described previously [27] and used to confirm the high 
quantification ability of pyrosequencing assays. 
 
2.9 Statistical analysis 
Association between clinicopathological factors and HPV-L1 status or DNA 
methylation was analyzed using the Fisher's exact test, χ2 test, Student’s t-test, ANOVA, 
and Kolmogorov-Smirnov test. Unsupervised two-way hierarchical clustering was 
performed using Cluster 3.0 software. Overall Survival (OS) was measured from 
registration date until date of PSCC-related death, filtering patients alive at last follow-
up and non-PSCC-related deaths. Estimation of OS distribution was performed by the 
Kaplan-Meier method. Differences between groups were determined by a log-rank test 
using R software (www.r-project.org/). P<0.05 was considered statistically significant. 
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3. Results  
3.1 Immunostaining analyses and HPV status  
Expression of p16INK4A and TP53 in HPV-associated OPSCC, HPV-negative 
OPSCC, and HPSCC was analyzed by IHC (Fig. 1B). HPV status was evaluated by 
PCR amplification of L1 region in high risk HPV with GP5/GP6 primers (Fig. 1C). All 
22 HPV-associated OPSCC samples that underwent IHC were p16(+), whereas only 
one HPV-negative OPSCC specimen was p16(+). Most p16(+) cases, except two, were 
TP53 wild-type.  
 
3.2 DNA methylation analysis using Infinium 450k and RNA-seq analysis 
We performed Infinium 450k BeadArray analysis on 13 clinical OPSCC and four 
non-cancerous mucosa samples (Fig. 2A). To analyze Infinium data, the probe nearest 
the TSS was selected for each gene, and β-values were compared by a t-test. A total of 
2,093 probes in high-CpG promoters had a P-value <0.05, and these were used for 
hierarchical clustering. 
Unsupervised 2-way hierarchical clustering analysis of 13 OPSCC and four 
normal mucosa samples classified these samples into two clusters. The low methylation 
cluster included the lowest methylation subgroup, consisting of the four non-cancerous 
mucosa samples, and a relatively low methylation subgroup of three OPSCC samples. 
The high methylation cluster included 10 OPSCC cases divided into two subgroups. 
Interestingly, all five HPV-L1(+) OPSCC samples were included in the high 
methylation cluster, forming a unique subcluster, whereas OPSCC samples with 
relatively low methylation were all HPV-L1(-). When a cluster of 487 genes were 
extracted from the 2,093 high-CpG genes, OPSCC samples showed markedly higher 
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methylation levels than non-cancerous samples (0.34±0.00 vs 0.16±0.00, P<1×10-30, t-
test) (Fig. 2A).  
We also investigated CpG island shore regions upstream and downstream from 
TSS, and gene body regions. The upstream CpG	 island	 shore	 regions	 were	significantly	 hypermethylated	 in	 cancer	 samples	 than	 non-cancerous	 samples	
(0.43±0.00 vs 0.35±0.01, P=3×10-30).	 These	 regions	 were	 already	 hypermethylated	to	 some	 extent	 in	 non-cancerous	 mucosa,	 and	 the	 methylation	 level	 did	 not	increase	 in	 cancer	 so	 markedly	 as	 observed	 in	 high-CpG	 promoter	 regions.	 The	downstream	 CpG	 island	 shore	 regions	 were	 generally	 hypermethylated	 in	 non-cancerous	 samples,	 and	 methylation	 levels	 in	 cancer	 were	 not	 significantly	different	 from	 non-cancerous	 samples	 (0.54±0.00 vs 0.55±0.00, P=0.2).	 Gene body 
regions showed	 aberrant	 hypomethylation	 in	 cancer;	 methylation	 levels	 were	decreased	 from	 0.72±0.00 in non-cancerous mucosa to 0.61 ± 0.00 in cancer	 (P<1×10-
30) (Fig. 2A).		Since	 methylation	 levels	 altered	 most	 apparently	 in	 high-CpG	 promoter	regions,	we	focused	on	these	regions	for	the	subsequent	analyses.	 
We next extracted frequently hypermethylated and silenced genes in OPSCC 
samples. Among the 13,221 high-CpG genes with an average β-value <0.2 in the four 
non-cancerous mucosa samples, 625 were hypermethylated (β-value >0.3) frequently in 
≥3 of 13 OPSCC samples (Fig. 2B). We next performed RNA-seq analysis on 
UMSCC47 and FaDu cell lines before and after Aza and/or TSA treatment, and found 
3,595 and 2,778 genes showing >2-fold upregulation in UMSCC47 and FaDu cell lines, 
respectively, compared to expression levels in untreated cells. Among the 625 
frequently hypermethylated genes, 144 were highly methylated (β-value >0.6) in at least 
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one cell line before Aza/TSA treatment, with a >2-fold upregulation after Aza/TSA 
treatment, accompanying a decrease in the β-value (Fig. 2B).  
For these 144 genes, we confirmed the unmethylated status in all four non-
cancerous mucosa samples and the hypermethylated status in OPSCC cases in the 
surrounding probes as well as the selected probe nearest to the TSS (Fig. 2C). GO terms 
related to cell-cell signaling and neuron differentiation were significantly enriched (Fig. 
2D).  
 
3.3 Validation of DNA methylation by pyrosequencing  
Nine genes were chosen from the 144 frequently silenced genes, including those 
related to relevant GO terms, and methylation levels were validated by quantitative 
methylation analysis by pyrosequencing. First, we analyzed the methylation level at the 
selected probe site using OPSCC and non-cancerous mucosa samples that were 
previously analyzed by Infinium (Fig. 3A). Methylation levels were confirmed to be 
highly similar. p16INK4A was additionally analyzed, and confirmed to be unmethylated 
in both non-cancerous mucosa and OPSCC samples.  
We next investigated the methylation status of these nine genes in pharyngeal 
cancer samples including 42 OPSCC and 15 hypo-pharyngeal SCC by pyrosequencing 
(Fig. 3B). Not only the selected probe site, but also the surrounding CpG sites were 
similarly hypermethylated, indicating that aberrant DNA methylation does not occur 
randomly at a single CpG site, but occurs at multiple consecutive CpG sites in a region 
near the TSS. When tumor samples were ordered (from the left) based on average 
methylation level, HPV-L1(+) samples were significantly enriched on the left (P=0.01, 
Kolmogorov-Smirnov test). This indicated that HPV-positivity significantly correlates 
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with frequent DNA hypermethylation. However, other clinicopathological factors such 
as age or smoking status were not significantly correlated with DNA methylation level. 
When DNA methylation levels were compared between HPV-L1(+) and HPV-L1(-) 
samples, significantly higher methylation was detected in all the cancer samples 
(P=0.0002, t-test) or in OPSCC samples (P=0.001, t-test).  
 
3.4 Comparison of HPV status, IHC data, and methylation status  
As p16INK4A is a surrogate marker of HPV infection, p16(+) status correlated 
strongly with HPV-L1(+). TP53-mutation(+) cases included 21 cases with nuclear 
staining and 16 cases with negative staining, and these were strongly, inversely 
correlated with p16(+) cases (Fig. 4A). To compare methylation status with HPV status 
and IHC data, we investigated the methylation status of the four most frequently 
methylated genes (RXRG, GHSR, CTNNA2, and ITGA4). Aberrant methylation was 
significantly correlated with HPV-L1(+) cases, and RXRG methylation showed a 
particularly strong correlation with HPV-positivity (P=3×10-5, χ2-test) (Fig. 4B). 
Despite the significant correlation, not only p16(+) cases, but also some p16(-) cases 
showed aberrant RXRG methylation.  
We also analyzed the association between clinicopathological factors and HPV-
L1 status, or RXRG methylation levels (Table 1). HPV-L1 positivity was associated 
significantly with tumor location (tonsils), p16(+), wild-type TP53, and alcohol(-) 
(P=0.002, 2×10-12, 3×10-8, 0.002, respectively). These associations were in good 
agreement with the previous reports that HPV-associated OPSCC arises within tonsils 
and base of tongue, that HPV-associated OPSCC patients do not intake excessive 
alcohol, and that TP53 mutation is generally found in HPV-negative cases, not in HPV-
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associated cases [28]. High RXRG methylation levels were also associated significantly 
with tumor location (tonsils), p16(+), and wild-type TP53 (P=0.04, 5×10-4, 0.002, 
respectively).  
We then investigated the association with prognosis. p16(+) cases and L1(+) 
cases, which are suggested to be HPV-associated tumors, were associated with 
significantly better prognosis than p16(-) cases (P = 0.002, log-rank test) and L1(-) 
cases (P=0.005), respectively (Fig. 5A). Whereas TP53-mutation did not predict 
outcome, RXRG-methylation(+) cases were significantly associated with better 
prognosis when analyzing all cancer cases (P=0.04) (Fig. 5A). When analyzing a 
p16(+) better-outcome group and a p16(-) poorer-outcome group separately, all the 
p16(+) cases showed good prognosis regardless of RXRG methylation status. Among 
p16(-) poorer-outcome patients, RXRG-methylation(+) correlated significantly with 
good prognosis (P=0.03) (Fig. 5B). From these results, two-step panel might be 
generated to predict prognosis. The first panel “p16 IHC” extracts p16(+) better-
outcome patients, and the second panel “RXRG methylation” additionally extracts 
RXRG-methylation(+) better-outcome patients among p16(-) group (Fig. 5C). 
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4. Discussion 
The involvement of epigenetic alterations in OPSCC has not been clarified; thus, 
we analyzed aberrant DNA methylation in OPSCC on a genome-wide scale using the 
Infinium 450k BeadArray. We identified frequently hypermethylated and silenced genes 
in OPSCC, such as RXRG, and showed that these genes are preferentially 
hypermethylated in HPV-positive tumors. p16INK4A is activated in HPV-positive tumors, 
and p16(+) cases show significantly better prognosis than p16(-) cases. Moreover, 
RXRG-methylation(+) cases significantly associated with better prognosis when 
analyzing all tumor cases, and also when analyzing the p16(-) poorer-outcome group.  
More than 10 genes were previously reported to be inactivated by DNA 
methylation in OPSCC [11, 29, 30], including p16INK4A, HOXA9, MGMT, GATA4, and 
RASSF1 [23, 30]. Herein, 144 genes were extracted as frequently hypermethylated and 
silenced in OPSCC, but p16INK4A was rarely methylated and was not included. GO 
terms related to neuron differentiation and cell development were enriched in these 
genes, in agreement with previous studies reporting that genes related to differentiation 
and development are targets of the polycomb complex in ES cells and that these genes 
are preferentially hypermethylated in many types of cancer [26, 31]. 
Lechner et al. reported 43 hypermethylated promoter regions associated with 
HPV in HNSCC through Infinium analysis, including three cadherins of the Polycomb 
group target genes [32]. Weiss et al. investigated promoter methylation of 12 genes 
(TIMP3, CDH1, p16INK4A, DAPK1, TCF21, CD44, MLH1, MGMT, RASSF1, CCNA1, 
LARS2, and CEPBA) by methylation-specific PCR, which is not a quantitative method, 
in a cohort of 55 HNSCC cases derived mostly from the oropharynx. HPV-associated 
tumors were significantly correlated with CCNA1 and TIMP3 promoter methylation 
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[23]. Schlecht et al. reported 22 CpG loci showing significant difference of methylation 
level between HPV-positive and HPV-negative OPSCC, which included four CpG loci 
at CDKN2A downstream region, but not promoter region around TSS [33]. O’Regan et 
al. showed frequent p16INK4A hypermethylation in HNSCC of anterior two thirds of the 
tongue, but no p16INK4A methylation in OPSCC [34]. The association of HPV-positive 
OPSCC with DNA hypermethylation of promoter regions, including p16 promoters, is 
thus still controversial. In this study, a highly quantitative analysis based on 
pyrosequencing revealed that hypermethylation of p16INK4A promoter region is very 
rare. Instead, promoter regions of 144 genes were found to be frequently 
hypermethylated in OPSCC, and analysis of nine genes showed that frequent DNA 
methylation is significantly correlated with HPV-positive status.  
Other than promoter CpG islands, CpG island shore and gene body regions were 
also analyzed. Gene body generally showed high methylation levels in non-cancerous 
mucosa, and significant decrease of methylation levels was observed in OPSCC. This is 
consistent with global DNA hypomethylation reported in many types of cancer [35]. 
CpG island shore regions upstream from TSS were hypermethylated in OPSCC, but the 
difference of methylation levels between cancer and non-cancerous samples was 
smaller than promoter regions. Aberrant DNA methylation is reported to occur from 
lower-CpG peripheral regions to higher-CpG regions in high-CpG promoters in 
carcinogenesis, and aberrant methylation at CpG island shore is frequently observed in 
the surrounding non-cancerous tissues [36, 37].  
The expression of p16INK4A is used as a surrogate marker of HPV infection. E6 
and E7 oncoproteins are known to inactivate TP53 and RB1, which enables the host 
cells to avoid apoptosis and proliferate; this simultaneously overstimulates cellular 
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senescence pathways because of cell cycle pathway feedback. p16INK4A is thus strongly 
expressed in HPV-positive OPSCC. Our data also indicated that hypermethylation of 
p16INK4A is not the cause of p16(-) status in HPV-negative cases. It has been reported 
that HPV-negative HNSCC featured novel focal deletions in CDKN2A [28]. Further 
analysis is necessary to clarify whether negative expression of p16 is due to gene 
mutation or other causes. Interestingly, although there was a significant correlation 
between DNA hypermethylation and HPV-positivity, a fraction of HPV-negative 
OPSCC also exhibited DNA hypermethylation. Whereas p16 positivity (thus HPV 
positivity) is a marker of better OPSCC prognosis [5, 6], RXRG-methylation(+) cases 
showed better outcome among all tumor cases, and even among the p16(-) poorer-
outcome group.  
Retinoid X receptors (RXRs) are  nuclear receptors for retinoids that have 
important roles in the regulation of growth and differentiation. RXRs have three 
separate isotypes encoded on three separate genes: RXRA, RXRB, and RXRG. Promoter 
hypermethylation of RXRG and the loss of gene expression were reported in lung cancer 
[38]. Although whether RXRG methylation plays a critical role in carcinogenesis is yet 
to be investigated, we identified frequent hypermethylation of RXRG in OPSCC and its 
significant correlation with better prognosis. Further studies are necessary to clarify 
how HPV infection is associated with DNA hypermethylation, or alternatively, whether 
there is another independent mechanism that confers relatively better outcome in 
OPSCC with higher DNA methylation. It is also reported that exposure to selective 
RXRG ligands decrease cellular proliferation of thyroid cancer cell lines expressing 
RXRG [39, 40]. Although further studies should be investigated, RXRG might be a 
potential target for treatment of RXRG-expressing cancer [41]. 
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In summary, in OPSCC, we identified frequently hypermethylated and silenced 
genes that are preferentially hypermethylated in HPV-associated tumors. While 
p16INK4A expression is known to be a marker of better prognosis in OPSCC, RXRG 
methylation(+) cases show better prognosis among all the cases as well as within p16(-) 
cases. 
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Fig. 1.  
The design of the study, immunostaining, and HPV status in OPSCC. (A) A flowchart 
showing the design of this study. (B) Immunostaining of p16 and TP53. Sections of 
OPSCC tissues were stained with hematoxylin and eosin (left), or analyzed by 
immunostaining for p16 (middle) and TP53 (right). TP53 was wild type in most p16(+) 
OPSCC samples (Case #1). Most of p16(-) OPSCC cases were TP53-mutation(+), 
showing either positive staining of TP53 (Case #2) or negative staining of TP53 (Case 
#3). Scale bar, 100 µm. (C) HPV infection status. The presence of a 142-bp PCR product 
for HPV-L1 region was analyzed by gel electrophoresis. Most p16(+) cases were HPV-
L1(+) (Case #1), whereas p16(-) cases were generally HPV-L1(-).  
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Fig. 2.  
Infinium 450k analysis of OPSCC and non-cancerous samples. (A) Genome-wide DNA 
methylation analyzed for 13 clinical OPSCC and four non-cancerous samples. A probe 
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nearest to the transcriptional start site (TSS) was selected for analysis of each promoter 
region. Probes with significantly different β-values between OPSCC and non-cancerous 
samples (P<0.05, t-test) were extracted, and 2,093 genes with high-CpG promoters 
(CpG score >0.48) were used for clustering (top). Genes with low-CpG promoters (CpG 
score <0.48), CpG island shore regions upstream and downstream from TSS, and gene 
body regions are additionally shown (middle). White: HPV-L1(-), age<60, smoking(-); 
black: HPV-L1(+), age>60, smoking(+) (bottom). Whereas three OPSCC samples with 
relatively low methylation formed a cluster with non-cancerous samples, other OPSCC 
samples comprised a cluster with high methylation. Methylation levels between tumor 
and non-cancerous samples were compared using t-test (right panels). The difference	 of	methylation	levels	was	the	most	apparent	in	high-CpG	promoter	region	(P<1×10-30, 
t-test). (B) There were 144 genes that met the following criteria: (i) unmethylated in 
four non-cancerous samples (average β-value <0.2); (ii) frequently hypermethylated in 
≥3 of 13 clinical OPSCC samples (β-value >0.3); (iii) hypermethylated in at least one 
cancer cell line before Aza/TSA treatment (β-value >0.6); (iv) de-methylated after 
Aza/TSA treatment (i.e. showing a decreased of β-value). (C) For the 144 frequently 
silenced genes, we confirmed that they were unmethylated in the four non-cancerous 
mucosa samples and hypermethylated in OPSCC cases in the surrounding probes as 
well as the selected probe nearest to the TSS. Representatively, GHSR was 
unmethylated in four non-cancerous samples (N), but OPSCC samples (T) were 
hypermethylated at the probe site nearest to the TSS and the surrounding probe sites as 
well. Arrowhead, the position of TSS. (D) For these genes, Gene Ontology (GO) terms 
related to cell-cell signaling and neuron differentiation were significantly enriched. 
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Fig. 3.  
Validation of DNA methylation in OPSCC samples by pyrosequencing. (A) Nine genes 
were chosen from the 144 frequently silenced genes. The methylation levels (analyzed 
In
fin
iu
m
Py
ro
se
qu
en
ci
ng
TNN/T
A
B
T
HPV-L1(+)
Location
Average of methylation level
N/T
Pyroseq
50
100
0%
β-value
1.0
0
0.5
GHSR
ITGA4
RXRG
UTF1
FAM19A4
CDH8
CTNNA2
NEFH
CASR
p16INK4A
GHSR
ITGA4
RXRG
UTF1
FAM19A4
CDH8
CTNNA2
NEFH
CASR
p16INK4A
3
2
1
2
1
2
1
2
1
3
2
1
3
2
1
3
2
1
2
1
2
1
2
1
GHSR
ITGA4
RXRG
UTF1
CDH8
CTNNA2
NEFH
CASR
p16INK4A
FAM19A4
Age>60
Smoking(+)
HPV-L1 Smoking
(-) 
(+)
Age
(<60) 
(>60)
(-) 
(+)
Location
(HPSCC) 
(OPSCC)
28/34		
by Infinium) are shown in the color scale (top), and the methylation levels at the probe 
site was also analyzed by pyrosequencing and shown (bottom), confirming similar 
results. p16 was additionally analyzed. (B) Pyrosequencing data of 70 pharyngeal 
cancer samples. To investigate the methylation status in other pharyngeal cancer 
samples and the relationship with clinicopathological factors (bottom), methylation 
levels in 42 OPSCC and 15 hypo-pharyngeal SCC samples were additionally analyzed 
by pyrosequencing (top). Closed boxes: HPV-L1(+), oropharyngeal, elder age >60 years 
old, smoking(+), respectively. Tumor samples were ordered from left to right based on 
average methylation level of the nine genes; HPV-L1(+) samples were significantly 
enriched on the left (P=0.01, Kolmogorov-Smirnov test), i.e. HPV infection correlated 
significantly with frequent hypermethylation. HPV-L1(+) samples were associated with 
higher methylation levels within all tumor samples (P=0.0002, t-test) and also within 
OPSCC (P=0.001, t-test). Frequent hypermethylation did not correlate with age or 
smoking status. Whereas red numbers indicated the CpG sites of the analyzed Infinium 
probes, the surrounding CpG sites as well as the probe site were shown to be 
hypermethylated at similar levels.  
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Fig. 4.  
Comparison of HPV status, immunostaining data, and methylation status in OPSCC 
samples. (A) Left, HPV-L1 status and IHC data of p16 and TP53 (See Figure 1 for 
representative results). Right, the methylation status of the four most frequently 
methylated genes (RXRG, GHSR, CTNNA2, and ITGA4). White, methylation level 
<50%. Black, methylation level ≥50%. HPV-L1(+) status correlated strongly with 
p16(+) status (P<1×10-15, Fisher’s exact test), and TP53-mutation(+) cases showed a 
strong inverse correlation with p16(+) cases (P=2×10-10). (B) Correlation between 
aberrant methylation and HPV-L1(+) status. For each of the four genes, especially 
RXRG, aberrant methylation significantly correlated with HPV-L1(+) samples.  
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Fig. 5.  
Analysis of prognosis in pharyngeal cancer cases. (A) Analysis of prognosis based on 
p16, HPV-L1, TP53 mutation, and RXRG methylation status. p16(+) cases were 
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significantly associated with better prognosis than p16(-) cases as reported (P=0.002, 
log-rank test), and HPV-L1(+) cases that were mostly p16(+) were also significantly 
correlated with better outcome (P=0.005). Whereas TP53-mutation did not predict 
outcome, RXRG-methylation(+) cases were significantly associated with better 
prognosis when analyzing all cancer cases (P=0.04). (B) RXRG methylation correlated 
with better outcome even when analyzing the p16(-) poorer-outcome group (P=0.03). 
p16(+) cases showed good prognosis regardless of RXRG methylation status. (C) Two-
step panel to predict the prognosis of OPSCC. The first and second panels classify 
patients into a good prognosis group with p16(+) and/or RXRG-methylation(+), and a 
poor prognosis group with p16(-) and RXRG-methylation(-).  
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Table 1. Clinicopathological factors and their association with DNA methylation  
            
  All cases HPSCC 
                                            
OPSCC   p-value RXRG methylation  
   
L1(+) L1(-) 
 
methylation(%) p-value 
# of samples (%) 70 15 24 31       
        Gender 
    
0.68 
 
0.38 
      Male 60 12 20 28 
 
36.3 ± 3.1 
       Female 10 3 4 3 
 
46.9 ± 10.2 
         Age 
    
1 
       >60 51 9 18 24 
 
38.4 ± 3.6 0.9 
     <60 19 6 6 7 
 
37.5 ± 6.0 
         Tumor location  
    
0.002 * 
 
0.04 * 
     tonsiles  34 - 21 13 
 
47.3 ± 4.1 
      base of tongue 8 - 3 5 
 
35.8 ± 9.5 
      soft palate 11 - 0 11 
 
30.0 ± 4.2 
      posterior wall 2 - 0 2 
 
44.4 ± 41.6 
         Clinical tumor 
classification 
    
0.19 
 
0.69 
     T1 6 0 0 6 
 
32.9 ± 8.2 
      T2 33 3 16 14 
 
43.5 ± 4.8 
      T3 16 5 5 6 
 
32.6 ± 6.3 
      T4a 14 7 2 5 
 
34.2 ± 6.6 
      T4b 1 0 1 0 
 
55 
         Clinical lymph node classification 
   
0.28 
 
0.09 
     N0 23 3 6 14 
 
30.4 ±  5.5 
      N1 4 2 1 1 
 
30.2 ± 13.7 
      N2a 3 0 3 0 
 
62.8 ± 13.9 
      N2b 25 6 9 10 
 
40.0 ± 4.6 
      N2c 12 4 3 5 
 
41.0 ± 8.3 
      N3 3 0 2 1 
 
57.8 ± 5.0 
         Lymph node metastasis 
    
0.16 
 
0.11 
     (+) 47 12 18 17 
 
41.8 ± 3.6 
      (-) 23 3 6 14 
 
30.4 ± 5.5 
         Clinical stage 
    
0.07 
 
0.09 
      I  6 0 0 6 
 
32.9 ± 8.2 
      II  11 0 5 6 
 
30.6 ± 10.5 
      III  8 4 2 2 
 
30.3 ± 8.8 
      IVA  39 11 12 16 
 
39.9 ± 4.1 
      IV B 6 0 5 1 
 
58.0 ± 2.0 
         p16 IHC 
    
1.6 x 10-12  * 
 
5.0 x 10-4  * 
     (+) 23 0 23 1 
 
52.9 ± 5.2 
      (-) 39 14 0 24 
 
29.4 ± 3.5 
      not perfomed  8 1 1 6 
           p53IHC 
    
3.0 x 10-8 * 
 
0.002  * 
     wild type 25 4 20 3 
 
50.7 ± 5.3 
      mutation 37 10 2 23 
 
29.6 ± 3.5 
      not performrd 8 1 2 5 
           Smoking status  
    
0.12 
 
0.85 
     (+) 51 8 17 26 
 
41.3 ± 3.4 
      (-) 9 1 6 2 
 
43.4 ± 10.4 
      no information 10 6 1 3 
           Alcohol status 
    
0.002 * 
 
0.19 
     (+) 47 9 12 26 
 
39.8 ± 3.7 
      (-) 12 0 10 2 
 
50.7 ± 7.0 
      no information 11 6 2 3      
OPSCC, oropharyngeal squamous cell carcinoma. HPSCC, hypo-pharyngeal squamous cell carcinoma. 
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